carbon monoxide (HBI-002) / Hillhurst Biopharma  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
carbon monoxide (HBI-002) / Hillhurst Biopharma
NCT03926819: A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers

Completed
1
20
US
HBI-002
Hillhurst Biopharmaceuticals, Inc., National Heart, Lung, and Blood Institute (NHLBI)
Anemia, Sickle Cell
04/23
04/23

Download Options